| Literature DB >> 28656939 |
Garima Thakur1, Amrinder Singh2, Inderbir Singh3.
Abstract
The present study reports the preparation and evaluation of polymer composites of chitosan and montmorillonite. The prepared polymer composites were evaluated for various powder properties and characterized by FTIR-ATR (Fourier Transform Infrared Spectroscopy- Attenuated Total Reflectance), XRD (X Ray Diffraction), and SEM (Scaning Electron Microscopy) techniques. Heckel and Kawakita equations indicated good compression characteristics of the composites. The polymer composites were employed in formulating sustained release tablets of aceclofenac. The formation of intercalated lamellar structures due to the entrapment of clay particles in the polymeric matrix network was found to be responsible for the drug release retardant behavior of the composites. The in vitro drug release data were fitted to various models like zero-order, first-order, Higuchi, Korsmeyer-Peppas, and Hixon and Crowell for studying the mechanism of drug release from the formulation. The value of release exponent (n) was found to range between 0.59 and 0.82, indicating non-Fickian (anomalous) drug release behavior. Swelling-induced diffusion of the drug through the polymer matrix and polymer matrix chain relaxation appeared to play a role in the release of the drug from the polymer composites.Entities:
Keywords: chitosan; chitosan-montmorillonite polymer composites; montmorillonite; sustained release; tablets
Year: 2015 PMID: 28656939 PMCID: PMC5198020 DOI: 10.3390/scipharm84040603
Source DB: PubMed Journal: Sci Pharm ISSN: 0036-8709
Formulation codes for the formulation of sustained release tablets.
| Ingredients (mg) | CS/MMT 11 | CS/MMT 41 | CS/MMT 14 |
|---|---|---|---|
| Acelofenac | 100 | 100 | 100 |
| Lactose | 70 | 70 | 70 |
| CS/MMT polymer composite | 25 | 25 | 25 |
| PVP K 30 | 25 | 25 | 25 |
| Talc | 2.5 | 2.5 | 2.5 |
| Magnesium stearate | 2.5 | 2.5 | 2.5 |
CS (chitosan); MMT (montmorillonite).
Values depicting the different micromeritic study parameters.
| S. No. | Parameter | CS/MMT 11 | CS/MMT 41 | CS/MMT 14 |
|---|---|---|---|---|
| 1 | Bulk density (g/cm3) | 0.54 ± 0.09 | 0.42 ± 0.11 | 0.47 ± 0.12 |
| 2 | Tapped density (g/cm3) | 0.62 ± 0.05 | 0.47 ± 0.08 | 0.52 ± 0.10 |
| 3 | Carr’s index (%) | 12.90 ± 0.42 | 10.63 ± 0.58 | 9.61 ± 0.72 |
| 4 | Hausner ratio | 1.15 ± 0.11 | 1.12 ± 0.08 | 1.11 ± 0.15 |
| 5 | Angle of repose (°) | 29.45 ± 0.89 | 31.14 ± 0.07 | 27.21 ± 0.98 |
| 6 | Swelling index (%) | 83.3 | 95 | 78.57 |
| 7 | pH | 5.1 | 4.9 | 5.2 |
| 8 | LOD (%) | 12.5 ± 0.56 | 16.5 ± 1.02 | 4.5 ± 0.34 |
| 9 | Effective pore radius (µm) | 12.8 ± 0.88 | 14.84 ± 0.95 | 11.37 ± 1.02 |
LOD: Loss On Drying.
Figure 1FTIR spectra of (A) Chitosan (CS); (B) Montmorillonite (MMT); (C) CS/MMT 11; (D) CS/MMT 41, and (E) CS/MMT 14.
Figure 2XRD pattern of (A) Chitosan; (B) Montmorillonite; and (C) CS/MMT polymer composite.
Figure 3Scaning Electron Microscopy (SEM) images of (A) pure chitosan, (B) pure montmorillonite and (C–F) CS/MMT polymer composite at different magnifications.
Figure 4Heckel plots for the tablets incorporating CS/MMT polymer composites as a sustained release in different ratios.
Parameters derived from the Heckel and Kawakita plots for tablets incorporating CS/MMT polymer conjugates as a sustained release agent prepared in different ratios.
| Samples | Heckel Analysis | Kawakita Analysis | ||||
|---|---|---|---|---|---|---|
| D0 | DA | DB | Py | DI | Pk | |
| CS/MMT 11 | 0.28 | 0.40 | 0.21 | 83.3 | 0.33 | 14.5 |
| CS/MMT 41 | 0.29 | 0.52 | 0.23 | 90.9 | 0.30 | 5.6 |
| CS/MMT 14 | 0.31 | 0.54 | 0.23 | 100 | 0.31 | 6.4 |
Figure 5Kawakita plots for the tablets incorporating CS/MMT polymer composites as a sustained release in different ratios.
Values depicting the size, friability, hardness, and tensile strength of the prepared sustained release tablets.
| Formulation Code | Diameter (mm) | Thickness (mm) | Friability (%) | Hardness (kg/cm2) | Tensile Strength (mN/cm2) | Drug Content (%) |
|---|---|---|---|---|---|---|
| CS/MMT 11 | 6.73 ± 0.04 | 3.81 ± 0.04 | 0.71 ± 0.10 | 4.0 ± 0.11 | 0.60 ± 0.05 | 98.89 ± 0.82 |
| CS/MMT 41 | 6.73 ± 0.04 | 3.75 ± 0.02 | 0.85 ± 0.12 | 4.5 ± 0.18 | 0.47 ± 0.09 | 99.12 ± 0.66 |
| CS/MMT 14 | 6.74 ± 0.02 | 3.75 ± 0.04 | 0.91 ± 0.08 | 4.5 ± 0.27 | 0.73 ± 0.08 | 98.87 ± 0.91 |
Figure 6In vitro dissolution profile of the CS/MMT sustained release tablets.
Release kinetics parameters of designed sustained release matrix tablets of aceclofenac.
| Batch No. | Zero Order | First Order | Higuchi | Korsmeyer-Peppas | Hixon Crowell | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| R² | k0 | R² | k1 | R² | kH | R² | kKP | n | R² | kHC | |
| 0.9694 | 0.1548 | 0.9348 | −0.0004 | 0.9719 | 3.9467 | 0.9859 | 0.2938 | 0.5946 | 0.9652 | −0.0038 | |
| 0.9662 | 0.1484 | 0.9871 | −0.0012 | 0.9914 | 3.9577 | 0.9899 | 0.244 | 0.790 | 0.9953 | −0.0033 | |
| 0.9629 | 0.1403 | 0.9865 | −0.001 | 0.9878 | 3.8081 | 0.9787 | 0.6316 | 0.827 | 0.9946 | 0.003 | |
Stability testing data of the sustained release tablets.
| Batch | Time Interval (months) | Test Parameters | ||
|---|---|---|---|---|
| Hardness (kg/cm2) | Friability (%) | Drug Content (%) | ||
| CS/MMT 11 | 0 | 3.56 ± 0.08 | 0.73 ± 0.05 | 99.1 ± 0.15 |
| 1 | 3.51 ± 0.15 | 0.79 ± 0.09 | 98.7 ± 0.20 | |
| 2 | 3.47 ± 0.10 | 0.79 ± 0.07 | 98.1 ± 0.56 | |
| 3 | 3.41 ± 0.20 | 0.82 ± 0.03 | 97.8 ± 0.15 | |
| CS/MMT 41 | 0 | 3.80 ± 0.15 | 0.54 ± 0.05 | 98.92 ± 0.70 |
| 1 | 3.71 ± 0.80 | 0.59 ± 0.06 | 98.67 ± 0.35 | |
| 2 | 3.65 ± 0.27 | 0.63 ± 0.02 | 98.1 ± 0.59 | |
| 3 | 3.50 ± 0.41 | 0.63 ± 0.07 | 97.34 ± 0.65 | |
| CS/MMT 14 | 0 | 4.25 ± 0.20 | 0.42 ± 0.02 | 98.99 ± 0.20 |
| 1 | 4.11 ± 0.17 | 0.44 ± 0.04 | 98.61 ± 0.19 | |
| 2 | 4.04 ± 0.31 | 0.47 ± 0.09 | 98.28 ± 0.35 | |
| 3 | 3.98 ± 0.24 | 0.49 ± 0.01 | 97.91 ± 0.55 | |